TMCI (TMCI) CEO John Treace purchases over 150,000 company shares in open market
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Treace Medical Concepts, Inc. Chief Executive Officer John T. Treace reported open-market purchases of the company’s common stock. On May 14, he bought 61,750 shares at a weighted average price of $2.6153 per share. On May 13, he bought 49,013 shares at $2.4592 per share, and on May 12, he bought 43,000 shares at $2.1739 per share, all in multiple transactions within stated price ranges. Following these purchases, he directly owns 7,158,313 shares, which include 542,784 restricted stock units, and also reports indirect holdings through trusts and his spouse while disclaiming beneficial ownership of those indirectly held shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 153,763 shares ($375,505)
Net Buy
7 txns
Insider
Treace John T.
Role
Chief Executive Officer
Bought
153,763 shs ($376K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 61,750 | $2.6153 | $161K |
| Purchase | Common Stock | 49,013 | $2.4592 | $121K |
| Purchase | Common Stock | 43,000 | $2.1739 | $93K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 7,158,313 shares (Direct, null);
Common Stock — 1,605,000 shares (Indirect, By spouse)
Footnotes (1)
- The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $1.9100 to $2.2800 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. Includes 542,784 restricted stock units The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $2.3850 to $2.5000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $2.4950 to $2.8000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. The Reporting Person disclaims beneficial ownership of shares held by his wife directly or in trusts for which his wife serves as trustee or co-trustee. The Reporting Person disclaims beneficial ownership of shares held in trust for which he serves as trustee or co-trustee.
Key Figures
Shares purchased May 12: 43,000 shares
Shares purchased May 13: 49,013 shares
Shares purchased May 14: 61,750 shares
+5 more
8 metrics
Shares purchased May 12
43,000 shares
Open-market purchase at $2.1739 per share
Shares purchased May 13
49,013 shares
Open-market purchase at $2.4592 per share
Shares purchased May 14
61,750 shares
Open-market purchase at $2.6153 per share
Total net shares bought
153,763 shares
Net-buy direction across three open-market purchases
Direct holdings after trades
7,158,313 shares
Common stock directly owned after May 14 purchases
Restricted stock units included
542,784 RSUs
Included within direct ownership total per footnote
Low end price range
$1.9100/share
Lower bound of disclosed trade price range in footnote
High end price range
$2.8000/share
Upper bound of disclosed trade price range in footnote
Key Terms
open-market purchase, weighted average purchase price, restricted stock units, beneficial ownership, +1 more
5 terms
open-market purchase financial
"transaction_action: open-market purchase"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
weighted average purchase price financial
"The price reported in Column 4 is a weighted average purchase price."
The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.
restricted stock units financial
"Includes 542,784 restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
beneficial ownership financial
"The Reporting Person disclaims beneficial ownership of shares held by his wife"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
co-trustee of a trust financial
"nature_of_ownership: As co-trustee of a trust"
FAQ
What insider transactions did TMCI CEO John T. Treace report on this Form 4?
John T. Treace reported open-market purchases of Treace Medical Concepts common stock. He bought 43,000 shares on May 12, 49,013 shares on May 13, and 61,750 shares on May 14, all at weighted average prices between about $2.17 and $2.62 per share.
What is John T. Treace’s direct ownership in TMCI after these purchases?
After the reported trades, John T. Treace directly owns 7,158,313 shares of Treace Medical Concepts. A footnote states this figure includes 542,784 restricted stock units, which are share-based awards that typically vest over time under the company’s equity plans.
At what prices did TMCI’s CEO purchase the common stock?
The CEO’s disclosed weighted average purchase prices were $2.1739, $2.4592, and $2.6153 per share. Footnotes explain each average reflects multiple trades within ranges from $1.91 up to $2.80 per share on the respective transaction dates.
Were the TMCI CEO’s reported purchases single trades or multiple transactions?
Each day’s purchase is reported as a weighted average price, indicating multiple underlying trades. Footnotes specify that the shares were bought in several transactions within stated price ranges and that detailed trade-level information is available upon request.